Actavis

Ireland-based Actavis has signed an agreement with Mayne Pharma to sell its US rights of Doryx brand acne treatment and related assets for around $50m.

Doryx (doxycycline hyclate delayed-release tablets) is a tetracycline-class antimicrobial, developed as adjunctive therapy for severe acne.

As part of the deal, Actavis will continue the packaging, distribution and promotion of the product for a transition period until 02 May, following the close of the deal.

Actavis North American Brands executive vice-president commercial William Meury said: "Actavis currently licenses and distributes Doryx in the US as part of our legacy Warner Chilcott partnership with Mayne, which is eligible to expire at the end of 2015.

"We are committed to investing in our expanded dermatology portfolio and in our R&D pipeline in this important category, and look forward to continuing to grow our business within dermatology."

"By agreeing to return the product to Mayne now, we receive value for the asset and, following a brief transition period, will enable our sales and marketing teams to focus their time and attention on supporting the expanded, industry-leading dermatology portfolio that will be part of our combined company following the acquisition of Allergan later this year.

"We are committed to investing in our expanded dermatology portfolio and in our R&D pipeline in this important category, and look forward to continuing to grow our business within dermatology."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The transaction is expected to be completed by the end of this month, noted Actavis.

Last week, Actavis signed an agreement with AstraZeneca to divest its branded respiratory business in the US and Canada, for an initial consideration of around $600m.

Under the agreement, Actavis will also receive an additional $100m from AstraZeneca, as well as agreed to multiple contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between both the firms.


Image: Actavis Biologics Ltd, Estuary Banks, Liverpool. Photo: courtesy of Rept0n1x.